DE69622527T2 - FORMULA FOR TOPICAL APPLICATION ON THE EYE CONTAINING OLOPATADINE FOR THE TREATMENT OF ALLERGIC EYE DISEASES - Google Patents

FORMULA FOR TOPICAL APPLICATION ON THE EYE CONTAINING OLOPATADINE FOR THE TREATMENT OF ALLERGIC EYE DISEASES

Info

Publication number
DE69622527T2
DE69622527T2 DE69622527T DE69622527T DE69622527T2 DE 69622527 T2 DE69622527 T2 DE 69622527T2 DE 69622527 T DE69622527 T DE 69622527T DE 69622527 T DE69622527 T DE 69622527T DE 69622527 T2 DE69622527 T2 DE 69622527T2
Authority
DE
Germany
Prior art keywords
eye
formula
treatment
allergic
topical application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69622527T
Other languages
German (de)
Other versions
DE69622527D1 (en
Inventor
John Michael Yanni
Stella M Robertson
Eiji Hayakawa
Masashi Nakakura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Alcon Vision LLC
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23864859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69622527(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kogyo Co Ltd, Alcon Laboratories Inc filed Critical Kyowa Hakko Kogyo Co Ltd
Application granted granted Critical
Publication of DE69622527D1 publication Critical patent/DE69622527D1/en
Publication of DE69622527T2 publication Critical patent/DE69622527T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)

Abstract

Topical ophthalmic formulations of the invention contain as an active ingredient 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid or a pharmaceutically acceptable salt thereof. The formulations are useful for treating allergic eye diseases such as allergic conjunctivitis, vernal conjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis.
DE69622527T 1995-06-06 1996-05-03 FORMULA FOR TOPICAL APPLICATION ON THE EYE CONTAINING OLOPATADINE FOR THE TREATMENT OF ALLERGIC EYE DISEASES Expired - Lifetime DE69622527T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/469,729 US5641805A (en) 1995-06-06 1995-06-06 Topical ophthalmic formulations for treating allergic eye diseases
PCT/US1996/006289 WO1996039147A2 (en) 1995-06-06 1996-05-03 Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases

Publications (2)

Publication Number Publication Date
DE69622527D1 DE69622527D1 (en) 2002-08-29
DE69622527T2 true DE69622527T2 (en) 2002-12-05

Family

ID=23864859

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69622527T Expired - Lifetime DE69622527T2 (en) 1995-06-06 1996-05-03 FORMULA FOR TOPICAL APPLICATION ON THE EYE CONTAINING OLOPATADINE FOR THE TREATMENT OF ALLERGIC EYE DISEASES
DE2002199034 Active DE10299034I2 (en) 1995-06-06 1996-05-03 Formulation for topical use on the eye containing olopatadine for the treatment of allergic eye diseases.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE2002199034 Active DE10299034I2 (en) 1995-06-06 1996-05-03 Formulation for topical use on the eye containing olopatadine for the treatment of allergic eye diseases.

Country Status (20)

Country Link
US (1) US5641805A (en)
EP (1) EP0799044B1 (en)
JP (1) JP3068858B2 (en)
KR (1) KR100202155B1 (en)
CN (1) CN1082367C (en)
AT (1) ATE220906T1 (en)
AU (1) AU698854B2 (en)
CA (1) CA2195094C (en)
DE (2) DE69622527T2 (en)
DK (1) DK0799044T3 (en)
ES (1) ES2179198T3 (en)
FI (1) FI970489A0 (en)
LU (1) LU90969I2 (en)
MX (1) MX9701013A (en)
MY (1) MY116651A (en)
NL (1) NL300101I2 (en)
NO (1) NO311637B1 (en)
PT (1) PT799044E (en)
TW (1) TW438588B (en)
WO (1) WO1996039147A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859000A (en) * 1995-06-07 1999-01-12 University Of Utah Research Foundation Method for reducing mast cell mediated allergic reactions
CA2306393C (en) * 1998-07-14 2008-12-23 Alcon Laboratories, Inc. Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization
US6174914B1 (en) 1999-06-15 2001-01-16 Alcon Laboratories, Inc. Method of inhibiting cytokine release from human ocular cells
EP1187617B1 (en) 1999-06-18 2004-03-03 Alcon Manufacturing Ltd. Method for selecting the concentration of an amphipathic antihistamine drug by determining the drug's surface activity rating
EP1250133B1 (en) 2000-01-25 2005-03-30 Alcon Inc. Ophthalmic anti-allergy compositions suitable for use with contact lenses
DK1282599T3 (en) 2000-05-19 2006-07-31 Alcon Inc Disulfide derivatives suitable for the treatment of allergic diseases
AU5722701A (en) 2000-05-19 2001-12-03 Alcon Universal Ltd Aniline disulfide derivatives for treating allergic diseases
AU2001253807B2 (en) 2000-05-19 2005-02-17 Alcon, Inc. Compositions containing a benzamide disulfide derivative for treating allergic diseases
CA2445269A1 (en) * 2001-05-03 2002-11-14 Novartis Ag Anti-ige antibody to treat ocular allergies
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7977376B2 (en) * 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
CN1599625A (en) * 2001-12-05 2005-03-23 爱尔康公司 Use of an h1 antagonist and a safe steroid to treat rhinitis
US20050209312A1 (en) * 2004-03-19 2005-09-22 Bausch & Lomb Incorporated Carboxylic acid derivatives of doxepin formulations preserved with low-irritation preservative
AU2005259911A1 (en) * 2004-06-28 2006-01-12 Alcon, Inc. Topical formulations for treating allergic diseases
MX2007005845A (en) * 2004-11-24 2007-07-04 Alcon Inc Method of delivering nasal spray.
US8101654B2 (en) * 2005-07-08 2012-01-24 Senju Pharmaceutical Co., Ltd. Percutaneously absorptive ophthalmic preparation comprising olopatadine
ES2594655T3 (en) 2006-03-31 2016-12-21 Vistakon Pharmaceuticals, Llc Treatment of eye allergies
US20080139531A1 (en) * 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
SI2114367T1 (en) 2007-02-07 2016-01-29 Novartis Ag Olopatadine formulations for topical nasal administration
CA2682730A1 (en) * 2007-04-11 2008-10-23 Alcon Research, Ltd. Use of an inhibitor of tnf.alpha. plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
CA2698651A1 (en) * 2007-09-06 2009-03-12 Kyowa Hakko Kirin Co., Ltd. Eye drop containing dibenz [b,e] oxepin derivative
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
IT1397503B1 (en) 2009-04-21 2013-01-16 F S I Fabbrica Italiana Sint PROCESS FOR THE PREPARATION OF OLOPATADIN
JP2012533554A (en) 2009-07-17 2012-12-27 アルコン リサーチ， リミテッド Olopatadine nasal spray regimen for children
WO2011027322A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Extended release dosage form containing olopatadine for oral administration
KR20120091037A (en) * 2009-10-01 2012-08-17 알콘 리서치, 리미티드 Olopatadine compositions and uses thereof
TW201206936A (en) 2010-07-19 2012-02-16 Alcon Res Ltd Methods and compositions for the treatment of allergy
TWI544922B (en) 2011-05-19 2016-08-11 愛爾康研究有限公司 High concentration olopatadine ophthalmic composition
CN103202833A (en) * 2012-12-25 2013-07-17 常州市亚邦医药研究所有限公司 Pharmaceutical composition of olopatadine or salts of olopatadine, and preparation method thereof
US20150119455A1 (en) * 2013-10-31 2015-04-30 Nephron Pharmaceuticals Corporation Formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4370324A (en) * 1980-09-17 1983-01-25 Bernstein Joel E Method and composition for treating and preventing irritation of the eyes
US4923892A (en) * 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
GB8520662D0 (en) * 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
JPS6310784A (en) * 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd Dibenz(b,e)oxepin derivative, antiallergic agent and anti-inflammatory agent

Also Published As

Publication number Publication date
EP0799044B1 (en) 2002-07-24
NL300101I2 (en) 2003-01-06
CN1161000A (en) 1997-10-01
NL300101I1 (en) 2002-12-02
FI970489A (en) 1997-02-05
JPH09510235A (en) 1997-10-14
WO1996039147A2 (en) 1996-12-12
PT799044E (en) 2002-11-29
DE10299034I2 (en) 2005-07-07
JP3068858B2 (en) 2000-07-24
ATE220906T1 (en) 2002-08-15
NO970517D0 (en) 1997-02-05
EP0799044A2 (en) 1997-10-08
FI970489A0 (en) 1997-02-05
NO970517L (en) 1997-04-03
AU698854B2 (en) 1998-11-12
CA2195094A1 (en) 1996-12-12
KR970704452A (en) 1997-09-06
TW438588B (en) 2001-06-07
US5641805A (en) 1997-06-24
WO1996039147A3 (en) 1997-02-20
LU90969I2 (en) 2002-12-02
DE10299034I1 (en) 2003-01-23
CN1082367C (en) 2002-04-10
DE69622527D1 (en) 2002-08-29
MX9701013A (en) 1997-05-31
ES2179198T3 (en) 2003-01-16
NO311637B1 (en) 2001-12-27
AU5726196A (en) 1996-12-24
DK0799044T3 (en) 2002-10-14
KR100202155B1 (en) 1999-06-15
MY116651A (en) 2004-03-31
CA2195094C (en) 2002-02-26

Similar Documents

Publication Publication Date Title
DE69622527D1 (en) FORMULA FOR TOPICAL APPLICATION ON THE EYE CONTAINING OLOPATADINE FOR THE TREATMENT OF ALLERGIC EYE DISEASES
MA26901A1 (en) NEW PHARMACEUTICAL COMPOSITION
KR950016738A (en) How to suppress Alzheimer's disease
ATE179888T1 (en) OPHTHALMIC PREPARATION FOR THE TREATMENT OR PREVENTION OF DRY EYE AND DISEASES CAUSED THEREFROM, CONTAINING 12-SULFODEHYDROABIC ACID
DE69930271D1 (en) MEDICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
RU95105435A (en) N-substituted 3-azabicyclo [3,2,0] heptane derivatives as neuroleptic agent
ATE325610T1 (en) XANTHINE DERIVATIVES FOR THE TREATMENT OF BRAIN SCHEMIA
DE69501359D1 (en) Use of phosphate diesters for the treatment of diseases of the retina
DE69500673D1 (en) Medicines for the therapeutic and prophylactic treatment of diseases caused by hyperplasia of the smooth muscle cells
EP0842663A4 (en) Ophthalmic preparations
DE69421457D1 (en) Use of N- (pyridinyl) -1H-indole-1-amines for the manufacture of a medicament for the treatment of obsessive-compulsive neurotic diseases
ATE215824T1 (en) AGENTS FOR REDUCING INTERNAL EYE PRESSURE
RU94045839A (en) 3-(phenulalkylaminoalkyloxy)-5-phenylpyrazole derivatives as well as process and intermediates for preparation thereof, drug containing said compounds
RU95107870A (en) Method to treat postoperative ciliochorioidal detachment
CA2219280A1 (en) Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers